Citations

Mayo Clinic

Clear

329 citation(s) found for "JACOBSON, R".

Serrated Polyposis Syndrome: A Review and Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Rex, Douglas K., Anderson, Joseph C., Burke, Carol A., Jacobson, Brian C , May, Folasade P. , Patel, Swati , Samadder, N. Jewel, Stoffel, Elena M. , Robertson, Douglas J.

American Journal of Gastroenterology | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004081 | PMID 42814894 Get It

Serrated polyposis syndrome (SPS) is the most common polyposis syndrome, yet SPS often goes unrecognized. SPS diagnosis is based on clinical criteria established by the World Health Organization and includes the size, cumulative lifetime number, and location of serrated polyps throughout the colon. Individuals with SPS have an increased risk of prevalent and incident colorectal cancer (CRC). Meticulous inspection, clearing of the colon and frequent surveillance colonoscopy is recommended to decrease incident CRC. Colorectal surgery is indicated for individuals diagnosed with cancer or whose polyp burden cannot be managed endoscopically by expert endoscopists. There is no common germline pathogenic variant associated with SPS. Germline genetic testing is indicated only in individuals who meet criteria for a known hereditary syndrome in the appropriate clinical setting. First-degree relatives of patients with SPS are at heightened risk of CRC and should undergo colonoscopic screening.
Cardiovascular Complications of Anaplasmosis: A Case of Acute Pulmonary Embolism and Literature Review
Gavrancic, Aleksandar, Jacobson, Christian M., Rabasovic, Veljko , Sviggum, Erik, Stojsavljevic, Jelena, Tarragona, Nestor, Mattingly, Peter J. , Dumic, Igor , Tarragona, Nestor G , Dumic, Igor , Sviggum, Erik

Infectious Disease Reports | June 24, 2026 | Volume: 18 | Issue: 3 | Pages: 62

10.3390/idr18030062 | PMID 42346069 Get It

Background: Anaplasmosis is an emerging tick-borne infection that typically presents as a non-specific febrile illness, with variable degrees of cytopenias and liver tests abnormalities. Severe complications remain atypical and uncommon. Case Report: We report a case of acute pulmonary embolism (PE) occurring during confirmed anaplasmosis in a 73-year-old male with no traditional thromboembolic risk factors. The patient presented with fever, constitutional symptoms, thrombocytopenia, leukopenia, and abnormal liver tests, raising suspicion for a tick-borne illness. Despite early clinical improvement on doxycycline, persistent tachycardia triggered further evaluation and uncovered an acute PE. Comprehensive workup at admission and repeated 14 months later excluded inherited and acquired thrombophilias, malignancies, autoimmune diseases, and alternative infectious etiologies. The patient was treated with doxycycline 100 mg orally twice daily for 10 days and anticoagulation with unfractionated heparin followed by 6 months of apixaban for a first episode of provoked PE. He attained complete clinical recovery without recurrence of thrombosis at the two-year follow-up. Discussion: Infectious diseases are increasingly recognized as contributors to thrombosis through inflammation-mediated hypercoagulability and endothelial dysfunction. Pulmonary involvement in anaplasmosis typically manifests as pneumonitis, pneumonia or acute respiratory distress syndrome, but thrombotic complications such as PE are exceedingly rare. This case highlights a rare but clinically significant vascular complication of anaplasmosis and underscores the importance of considering thromboembolic events in patients with persistent or unexplained tachycardia. Conclusions: As the incidence of anaplasmosis continues to rise, greater awareness of its potential cardiovascular manifestations is essential. Early recognition and prompt treatment with doxycycline remain critical, while further studies are needed to better define the thrombotic risk associated with this infection.
Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Jacobson, Caron A. , Ahmed, Sairah, Lin, Yi, Perales, Miguel-Angel, Lunning, Matthew A. , Herr, Megan, Hill, Brian T., Ganguly, Siddhartha, Perez, Waleska, Feng, Zhongyu, Best, Timothy, Lee, Grace, Nikolajeva, Olga , Du, Brad, Adedokun, Babatunde, Locke, Frederick L., Siddiqi, Tanya , Ahmed, Sairah , Ghobadi, Armin , Miklos, David B. , Perales, Miguel‐Angel , Herr, Megan M. , Hill, Brian T. , Ganguly, Siddhartha , Lee, Grace, Jaglowski, Samantha , Locke, Frederick L.

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7028-7028

10.1200/jco.2026.44.16_suppl.7028 Get It

7028 Background: Axi-cel, autologous anti-CD19 CAR T-cell therapy, showed long-term survival and curative potential in R/R LBCL (ZUMA-1; Neelapu et al. Blood . 2023). Few studies have examined long-term outcomes beyond clinical trials. Here we report long-term real-world outcomes of axi-cel in R/R LBCL using large-sample CIBMTR data. Methods: A total of 1500 adults from 79 US centers receiving commercial axi-cel after ≥2 LOT for LBCL from Oct 2017-Aug 2020 were enrolled in a post-marketing requirement study. A protocol was developed prior to the study’s implementation, reviewed by Kite and CIBMTR. This is a secondary analysis of said study. Key outcomes were progression-free survival (PFS), overall survival (OS), time to next therapy (TTNT), disease-specific mortality (competing risks were non-relapse deaths), subsequent malignancies, and non-relapse mortality (NRM). Outcomes were analyzed descriptively. Cases with missing data were excluded separately for each endpoint. Results: As of Aug 2025, 1446 patients (pts) were included in the analysis. Median age at infusion was 62.2 y (range, 19.6-90.8: 38% of pts ≥65 y); 65% were male. Five percent of pts had ECOG PS ≥2 and 16% had high-grade lymphoma. Pts had a median of 3 (range, 2-4) prior LOT, 28% had prior autologous hematopoietic cell transplantation, and 50% received bridging therapy. At 59.7 mo median follow-up, median PFS (95% CI) was 7.9 mo (6.3-10.9) and 5-y PFS was 30% (27-32). The median OS was 25.7 mo (21.6-30.2); 5-y OS was 38% (35-41). The 5-y cumulative incidence of disease-specific mortality was 51%. Among pts who were progression-free at 2, 3, 4, or 5 y post-infusion, the OS at 6 y (95% CI) was 73% (68-78), 81% (76-86), 90% (84-94), and 94% (89-97), respectively. The median duration of response (DOR) was 25.3 mo (95% CI, 20.7-32.8) and 5-y DOR was 38% (35-41). The median TTNT was 12.2 mo and 30% did not need additional LOT at 5 y. Of pts who received subsequent salvage therapy, 12 (2%) received cell therapy, 39 (7%) received hematopoietic cell transplant, and 475 (90%) received other therapy. The 1, 2, 3, 4, and 5-y cumulative incidence of relapse (95% CI) was 49% (46-51), 52% (50-55), 54% (52-57), 55% (53-58), and 56% (53-59), respectively. No new safety signals were observed. The primary causes of death (n=864; 60%) were primary disease (540; 63%), infection (111; 13%), and organ failure (57; 7%). The 5-y cumulative incidence of NRM was 16% (95% CI, 14-18). At 5 y, 11% (95% CI, 10-13) had subsequent malignancies, mostly therapy-related myeloid neoplasms (6%) and non-melanoma skin cancer (3%); none were directly attributed to axi-cel. Conclusions: This real-world study showed sustained survival at 5 y among pts with R/R LBCL treated with axi-cel after ≥2 LOT, consistent with ZUMA-1. Infection and organ failure were common causes of NRM. These results continue to support the use of axi-cel with curative intent in R/R LBCL.
Human Papillomavirus Test Agreement Between Self-Collected Vaginal and Clinician-Collected Cervical Specimens
Cyriac, Jissy , Theel, Elitza S. , Long, Margaret E. , Maxson, Julie, Cole, Kristin C., Lin, Iris, McCann, J P, Gallagher, Elise M., Meunier, Matthew R., Rutten, Lila J. Finney, Binnicker, Matthew J. , MacLaughlin, Kathy L. , Maxson, Julie A, McCann, Jainnee, McCann, Jainnee, Meunier, Matthew R. , Jacobson, Robert M. , Rutten, Lila J. Finney

Journal of Lower Genital Tract Disease | May 26, 2026 | Volume: 30 | Issue: 3 | Pages: 161-168

10.1097/lgt.0000000000000962 | PMID 42185049 Get It

Objectives: We evaluated agreement between human papillomavirus (HPV) tests performed on self-collected vaginal and clinician-collected cervical specimens to advance HPV self-collection as a cervical cancer screening option in our health care system. Methods: This diagnostic accuracy study was conducted at an academic medical center. Participants were 25–65 years old with upcoming colposcopy appointments. One cohort (n = 79) self-collected a vaginal specimen in the clinic immediately before a clinician-collected cervical specimen. The second cohort (n = 115) self-collected a vaginal specimen at home, mailed it in, and had a clinician-collected cervical specimen in the clinic. Paired specimens were evaluated for total (TPA), positive (PPA), and negative (NPA) percentage agreement. Extreme temperature stability studies were also conducted. Results: Compared with clinician-collected cervical specimens, in-clinic self-collected vaginal specimens showed a TPA, PPA, and NPA of 98%, 100%, and 97% for HPV16; 99%, 100%, and 99% for HPV18; 86%, 94%, and 79% for high-risk other (HRO) HPV. The TPA, PPA, and NPA for at-home self-collected vaginal specimens compared with clinician-collected cervical specimens were 94%, 79%, and 96% for HPV16; 95%, 43%, and 98% for HPV18; 89%, 80%, and 93% for HRO. Vaginal specimens showed prolonged stability and were unaffected by extreme temperatures. Conclusions: In general, in-clinic and at-home self-collected vaginal HPV specimens for HPV screening demonstrate high agreement with clinician-collected cervical specimens, with the exception of low PPA in the at-home self-collected vaginal HPV18 subgroup. Our findings support the use of HPV self-collection as a practical option to expand access to cervical cancer screening.
Prevention and management of vaccine hesitancy
Reis, Christopher , JACOBSON, R, Jacobson, Robert M. , Reis, Christopher A. , Jacobson, Robert M

Srpski medicinski casopis Lekarske komore | April 4, 2026 | Volume: 7 | Issue: 1 | Pages: 15-22

10.5937/smclk7-62537 Get It

Vaccine hesitancy refers to the delay in accepting or refusing vaccines despite the availability of vaccination services. Well-conducted studies and trials reviewed in this article support methods both to prevent and manage vaccine hesitancy. Clinicians should know which vaccines their patients are due to receive and should use every encounter to address this issue. Research shows clinicians' recommendations increase vaccine uptake. Recommendations that patients perceive as stronger have a greater effect in increasing vaccine uptake. Using presumptive language to phrase the recommendation is more effective than presenting the vaccine conversationally as an option for the patient. When the patient counters the strong recommendation with hesitancy, the clinician should engage the patient with motivational interviewing, perhaps using a four-step process called the "Four A's".
Risk of Multiple Sclerosis Among Persons With Epstein-Barr Virus–Positive Mononucleosis
Hall, Susan A. , Jacobson, Robert M. , Keegan, B. Mark, Fan, Chun , McPhee, Roderick , Buck, Philip O. , Diaz-Decaro, John, Keegan, B. Mark , Keegan, B Mark , Jacobson, Robert M , Sauver, Jennifer L. St. , Diaz‐Decaro, John

Neurology Open Access | April 1, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.1212/wn9.0000000000000082 | PMID 42022360 Get It

Herpesvirus genome integration in whole‐genome sequences of dementia and control cohorts
Piotrowski, Stacey L. , Allnutt, Mary Alice , Johnson, Kory, Ferrucci, Luigi, Morris, Huw, Hardy, John, Ryten, Mina, Logroscino, Giancarlo, Troncoso, Juan C. , Beach, Thomas G., Serrano, Geidy E., Cruchaga, Carlos, Ross, Owen A., Chiò, Adriano, Ding, Jinhui, Scholz, Sonja W. , Jacobson, Steven, Hardy, John , May, Patrick , Scholz, Sonja W , Hardy, John , May, Patrick , Houlden, Henry , Johnson, Kory, Tanaka, Toshiko , Ferrucci, Luigi , Ryten, Mina , Logroscino, Giancarlo , Beach, Thomas G. , Serrano, Geidy E. , Cruchaga, Carlos , Dickson, Dennis W. , Ross, Owen A. , Chiò, Adriano , Houlden, Henry , Dalgard, Clifton L. , Ding, Jinhui , Gibbs, J. Raphael , Traynor, Bryan J. , Jacobson, Steven

Alzheimer's & Dementia | March 19, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71047 | PMID 41853978 Get It

Abstract INTRODUCTION The infectious hypothesis suggests that microbes like herpesviruses may play a role in the pathogenesis of Alzheimer's disease (AD) and other related dementias through methods that may include viral genome integration. The occurrence of herpesvirus genome integration in dementia patients has not been thoroughly characterized. METHODS Over 7500 total whole‐genome sequences from control, frontotemporal dementia/amyotrophic lateral sclerosis spectrum, Lewy body dementia (LBD), multiple system atrophy (MSA), and AD cohorts were screened for the integration of pathogen genomes using the PathSeq computational tool. RESULTS Low PathSeq scores for human herpesvirus 6 (HHV‐6) were consistent with the suspected integration of viral genome segments. The LBD and MSA cohorts had a significantly higher prevalence of this partial HHV‐6 genome integration. DISCUSSION This higher prevalence in both synucleinopathies was not noted in other herpesviruses, suggesting that the integration of HHV‐6 may play a role in a subset of these patients. Highlights Over 7500 whole‐genome sequences from controls and dementia patients were analyzed. Sequences consistent with integrated herpesviruses were identified using PathSeq. Prevalence of partial HHV‐6 integration was higher in synucleinopathies. Herpesviruses genome integration may play a role in subsets of dementia patients.
Conversational AI to improve preventive care in rural America: co-designing with healthcare providers and parent-adolescent dyads
Argyris, Young Anna , Town, Mya, Darr, Francis J. A. , Klee, David , Winn, Brian , English, B. Keith , Tan, Pang-Ning , Kordjamshidi, Parisa , Gogineni, Kamalika , Klee, David, Winn, Brian , Jacobson, Robert M. , Tan, Pang-Ning

BMJ Innovations | March 19, 2026 | Volume: 12 | Issue: 3 | Pages: 234-239

10.1136/bmjinnov-2025-001473 Get It

Background While rural health guidelines have often cautioned against digital interventions due to infrastructure and literacy barriers, this study introduces an SMS-based conversational artificial intelligence (CAI) that overcomes these limitations to promote HPV vaccination. Objective To evaluate an SMS-based CAI using the Centers for Disease Control (CDC)’s presumptive and CASE (Corroborate, About Me, Science and Explain) frameworks to promote HPV vaccination among rural parent-adolescent dyads by: (1) testing its usability; (2) assessing the feasibility of co-design with clinicians and parent-adolescents; (3) identifying adoption barriers and (4) examining communication preferences across behavioural profiles. Methods We developed a CAI simulator using the presumptive approach and the structured CASE method to address 11 common concerns about the HPV vaccine. A multimethod usability study with 13 rural parent-adolescent dyads (n=26) included in-depth interviews and the System Usability Scale. Results The CAI achieved excellent usability (mean SUS 85.2, ~96th percentile). A previously undocumented behavioural profile—vaccine-unaware—was identified, distinct from hesitancy, and best addressed through empathetic, exploratory dialogue. Key adoption barriers included integration with existing preventive care routines and endorsement by trusted local providers. Conclusions Contrary to the assumption that rural residents resist digital tools, participants engaged readily when content was credible, locally endorsed and accessible via SMS. Findings highlight the conditional effectiveness of the CDC’s presumptive style in CAIs—well-suited for vaccine-compliant users but less effective for sceptical or unaware groups, who, we argue, would respond better to conversational, empathetic tones.
Barriers to airway procurement processes in sub-Saharan Africa: An exploratory qualitative study
Patel, Nina R. , Kabagenyi, Fiona , Tshite, Felicia , Barnor, Isaac , Abdalla, Tagwa H.A. , Maina, Reuel K. , Wiedermann, Josh, Jacobson, Lia , Okerosi, Samuel , Balakrishnan, Karthik , Patterson, Rolvix H. , Sidell, Douglas, Xu, Mary Jue , Patel, Nina , Sidell, Douglas R. , Wiedermann, Joshua , Balakrishnan, Karthik , Sidell, Douglas R , Din, Taseer , Patterson, Rolvix H , Sidell, Douglas R. , Din, Taseer

Journal of the Colleges of Medicine of South Africa | March 12, 2026 | Volume: 4 | Issue: 1 | Pages: No page available

10.4102/jcmsa.v4i1.257 | PMID 41958947 Get It

Background: Access to high-quality airway equipment is critical for effective otolaryngological and emergency care. In sub-Saharan Africa (SSA), challenges in the procurement infrastructure may hinder equipment availability, impacting patient outcomes. Given the paucity of literature investigating equipment procurement in SSA, this study aims to map out the multilevel barriers to procurement of airway equipment in SSA to inform opportunities for improvement. Methods: A qualitative study design was employed using semi-structured interviews and open-ended survey responses. Participants included otolaryngologists in SSA, manufacturing company representatives and international policymakers, selected through purposive sampling to ensure representation of various roles in the procurement process. Six interviews, one focus group and six survey responses with regional healthcare providers (n = 13), manufacturing representatives (n = 3) and international policymakers (n = 2) explored supply chain dynamics, regulatory challenges, manufacturing capabilities, financial constraints and policy frameworks. Data were analysed using thematic analysis to identify recurrent themes and interrelationships. Results: Systemic barriers exist in the procurement process, including fragmented supply chains, inconsistent regulatory enforcement, limited local manufacturing capacity and insufficient funding mechanisms. Otolaryngologists emphasised frequent delays in equipment availability, while manufacturers reported logistical challenges and regulatory hurdles. Policymakers noted gaps in infrastructure and regional coordination. Emerging themes suggest opportunities for streamlining procurement processes, fostering local production and enhancing collaboration to improve supply chain efficiency. Conclusion: This study underscores the multifaceted challenges in airway equipment procurement in SSA and highlights the need for integrated approaches involving stakeholders across the supply chain. Contribution: Findings provide actionable insights to inform policy development and capacity-building initiatives with the goal of enhancing access to life-saving airway equipment and improving healthcare outcomes.
Factors Affecting Nurses' Ability to Identify Delirium in Acute Care Settings
Hook, Mary L., Lindroth, Heidi L., McGuire, Dana, Reopelle, Stephanie L, Strand, Stephanie A., Jacobson, Nora , Hook, Mary L. , Lindroth, Heidi

Research in Gerontological Nursing | March 9, 2026 | Volume: 19 | Issue: 3 | Pages: 109-121

10.3928/19404921-20260303-02 | PMID 41800940 Get It

Purpose: Delirium is a serious underrecognized health condition in hospitalized older adults. The current qualitative study used dimensional analysis to increase understanding of the clinical reasoning processes used by acute care nurses to assess for delirium. Method: Ten focus groups with experienced medical, surgical, and intensive care nurses ( N = 39) from quaternary, community, and academic medical centers discussed their application of clinical reasoning processes to assess/detect delirium symptoms. Transcripts were inductively analyzed. Trustworthiness was checked with a subset of participants ( n = 12). Results: Findings illustrate how nurses apply clinical reasoning to recognize and respond to delirium symptoms and navigate clinical and social structures to maintain patient safety. Clinical context and social structures are important conditions influencing nurse reasoning and judgment. Conclusion: Further process improvement and research efforts should explore strategies to enhance interdisciplinary shared knowledge within a supportive environment to improve the detection and care to lessen the severity and duration of delirium for vulnerable patients.